Teamwork Financial Advisors LLC Decreases Stake in Danaher Co. (NYSE:DHR)

Teamwork Financial Advisors LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 58.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,124 shares of the conglomerate’s stock after selling 1,580 shares during the period. Teamwork Financial Advisors LLC’s holdings in Danaher were worth $258,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher during the fourth quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the 3rd quarter valued at approximately $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter worth $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $244.19 on Thursday. The company has a market cap of $176.38 billion, a P/E ratio of 46.60, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The company’s 50-day moving average price is $234.90 and its 200-day moving average price is $253.47.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business earned $2.02 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analysts Set New Price Targets

DHR has been the topic of several recent research reports. Barclays lowered their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. TD Cowen boosted their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Guggenheim began coverage on Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research report on Friday, December 13th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.